---
title: "哈药集团人民同泰医药股份有限公司 (600829.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/600829.SH.md"
symbol: "600829.SH"
name: "哈药集团人民同泰医药股份有限公司"
industry: "医疗产品分销商"
---

# 哈药集团人民同泰医药股份有限公司 (600829.SH)

| Item | Detail |
|------|--------|
| Industry | 医疗产品分销商 |
| Location | 沪深市场 |
| Website | [www.hyrmtt.com.cn](https://www.hyrmtt.com.cn) |

## Company Profile

公司于 2015 年 4 月经重大资产重组后由哈药集团三精制药股份有限公司更名而来，公司以先进的经营理念和专业化的优质服务，树立起 “从商有德、诚信服务” 的医药商业领导品牌，在全国医药商业的各项排名榜上，均处于领先地位。公司主营业务涵盖医药批发业务、医药零售业务、医药物流服务及医疗服务。公司主要经营化学药、中成药、生物制品，同时销售医疗器械、中药饮片、保健食品、日用品、玻璃仪器、化学试剂等。公司获得的荣誉有：先进基层工会、支援老区先进单位、最佳设计奖、质量管理小组活动优秀企业、2010 年度纳税贡献大户、2020 诚信建设示范单位、“2023 年度医药冷链仓储能力 TOP30”、“医药冷链最...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.45)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 14 / 25 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.26% |  |
| Net Profit YoY | -53.75% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.07 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.20B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 10.22B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.06% | C |
| Profit Margin | 1.17% | C |
| Gross Margin | 8.11% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.26% | D |
| Net Profit YoY | -53.75% | D |
| Total Assets YoY | -0.13% | D |
| Net Assets YoY | 4.14% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 8574.57% | A |
| OCF YoY | -0.26% | D |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.45 | A |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 57.38% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 哈药集团人民同泰医药股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.06%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "1.17%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "8.11%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.26%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-53.75%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.13%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.14%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "8574.57%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-0.26%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.45",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "57.38%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 华东医药 (SZ.000963) | B | C | A | B | B | B |
| 02 | 九州通 (SH.600998) | C | B | A | D | B | B |
| 03 | 国药股份 (SH.600511) | C | C | A | C | B | B |
| 04 | 上海医药 (SH.601607) | C | C | A | D | B | C |
| 05 | 白云山 (SH.600332) | C | C | A | C | B | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 52.03 | 16/26 | 54.95 | 30.48 | 23.26 |
| PB | 2.07 | 17/26 | 2.19 | 1.64 | 1.49 |
| PS (TTM) | 0.61 | 15/26 | 0.64 | 0.47 | 0.43 |
| Dividend Yield | 0.00% | - | 1.98% | 1.92% | 1.76% |

## References

- [Company Overview](https://longbridge.com/en/quote/600829.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/600829.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/600829.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
